|Videos|August 26, 2020

COVID-19 Is Not Driving Better Healthcare Discussion

Brad Spellberg, MD, explains how real progress can be made to a debted system with worsened rates of user health.

Coronavirus 2019 (COVID-19) has been many people’s introduction to unique facets of medicine: drug and vaccine development, research and academics, even hospital resourcing.

But, especially given the toll the pandemic has taken on the US, many have posited whether it’s influenced people’s perception of the federal healthcare system—one that’s become synonymous with spending and debate over access versus choice.

There’s also the common notion that infectious disease, a subspecialty with limited budgeting and dwindled resources, will see a boom in personnel and future interest due to COVID-19.

Unfortunately, Brad Spellberg, MD, doesn’t see either to be true.

In an interview with Contagion, Spellberg, chief medical officer of the Los Angeles County and University of Southern California Medical Center, and author of the book Broken, Bankrupt and Dying, said he believes infectious disease will continue to lose out indebted medical school students to more financially promising specialties like cardiology and dermatology after the pandemic.

“Medical school debt is what it is,” he said. “ID physician salaries are what they are.”

His means for improved infectious disease status are two-fold: better leadership, and a uniform call for healthcare reform.

“We spend 2 to 2.5 times more per capita and per GDP than our peer nations,” Spellberg said. “And for that massive excess cost, we live shorter lives and have higher mortality rates. Americans are being ripped off by our healthcare system.”

His suggestion is the US looks to nations like Australia and New Zealand, which have both established successful systems that allow single- and multi-payer options to coexist. Nothing would be more American, Spellberg quipped, than to allow conflicting healthcare ideologies play out simultaneously.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.